Core Insights - Intelligent Bio Solutions (INBS) has expanded its presence in the U.S. forensic market through a partnership with SMARTOX, enhancing its drug detection capabilities using fingerprint sweat technology [1][2][8] - The collaboration is expected to improve operational efficiency and hygiene in drug testing, while also positioning INBS for broader market expansion, including workplace drug testing [2][4][9] - INBS's stock has seen a year-to-date increase of 36.4%, significantly outperforming the industry average of 2.6% [3] Company Developments - The partnership with SMARTOX allows INBS to leverage a strong distribution network, facilitating the deployment of over 50 drug screening devices across various U.S. institutions, resulting in over 7,000 tests conducted [8] - INBS is pursuing FDA 510(k) clearance for its opiate test system, which will enable entry into high-value markets such as workplace safety and clinical diagnostics [9] - The company currently has a market capitalization of $13.2 million and anticipates an 80.4% growth in earnings for 2025 [5] Industry Outlook - The global drug screening market is projected to grow from $9.1 billion in 2024 to $19.5 billion by 2029, with a compound annual growth rate (CAGR) of 16.6%, driven by increased drug consumption and stricter testing regulations [10]

Core Insights - Intelligent Bio Solutions Inc. (INBS) is expanding its presence in the U.S. Forensic Use Only Market through a partnership with SMARTOX, having deployed over 50 Intelligent Fingerprinting Drug Screening Readers and conducted over 7,000 screening tests, including more than 1,500 in 2024 [1][2][3] Company Overview - INBS specializes in intelligent, rapid, non-invasive testing solutions, particularly in drug screening technology that reduces reliance on invasive methods [2][7] - SMARTOX, founded in 2012, provides drug and alcohol testing products and services across various sectors, including healthcare and criminal justice, and is committed to innovation and customer service [6] Market Demand and Technology - There is an accelerated demand for non-invasive, rapid testing in forensic settings, with INBS's technology credited for improving efficiency and user dignity while simplifying operations [2][5] - The Intelligent Fingerprinting Drug Screening System allows for hygienic, non-invasive drug screening in under ten minutes using fingerprint sweat, which is beneficial for safety-critical industries [4][7] Regulatory Efforts - INBS is actively pursuing FDA clearance for its opiate test system for codeine, aiming for broader market expansion in 2025, including workplace drug testing [3][4]